Chinese Hepatolgy ›› 2024, Vol. 29 ›› Issue (12): 1498-1502.

• Liver Cancer • Previous Articles     Next Articles

The diagnostic value of combined detection of serum APE1 and miR183 in primary hepatocellular carcinoma

JIAN Hui-ling1, GAO Li-xia1, LI Gui-yuan2, ZHU Hai-peng1, LI Di1, JIA Xiao-ling1, HU Jun1   

  1. 1. Department of Hematologic Oncology , Karamay Central Hospital of Xinjiang, Xinjiang Clinical Research Center for precision medicine of digestive system tumor, Xinjiang Key Laboratory of Clinical Genetic Testing and Biomedical Information, Karamay 834000, China;
    2. Department of Medical Oncology, Shanghai Tongji Hospital, Shanghai 200065, China
  • Received:2023-09-30 Online:2024-12-31 Published:2025-02-19
  • Contact: HU Jun

PDF (PC)

10

Abstract: Objective To investigate the value of combined detection of serum apurinic/apyrimidinic endonuclease 1 (APE1) and microRNA183 (miR183) in the diagnosis of primary hepatocellular carcinoma.Methods Enzyme-linked immunosorbent assay (ELISA) was used to detect the serum APE1 protein level in 60 healthy individuals (normal group), 180 high-risk patients with hepatocellular carcinoma (high-risk group) and 60 hepatocellular carcinoma patients (hepatocellular carcinoma group). The levels of the serum miR183 in the three groups were detected by real-time fluorescent quantitative polymerase chain reaction (RT-qPCR). Receiver operating characteristic (ROC) curve analysis was used to explore the value of combined detection of APE1 and miR183 in the diagnosis of hepatocellular carcinoma.Results The detection results of APE1 in the hepatocellular carcinomar group were 92.39 (70.76, 418.99) IU/mL, while those in the high-risk group were 88.96 (77.27, 406.28) IU/mL, both of which were higher than the normal group 75.79 (65.09, 81.97) IU/mL (P<0.001), but there was no significant difference between the hepatocellular carcinoma group and the high-risk group (P=0.714). The relative expression of miR183 in the hepatocellular carcinoma group was 2.35 (1.02, 4.15), the high-risk group was 1.38 (0.76, 3.13), and the normal group was 0.98 (0.70, 2.01). The results in hepatocellular carcinoma group were significantly higher than the other two groups (P<0.05), but there was no significant difference between the high-risk group and the normal group (P=0.166). The area under the curve (AUC) of APE1 alone in the diagnosis of hepatocellular carcinoma was 0.703 (95%CI: 0.607-0.799), the diagnostic cut-off value was 94.7 IU/mL, the sensitivity was 50%, and the specificity was 99.5%. The AUC of miR183 alone in the diagnosis of hepatocellular carcinoma was 0.723 (95%CI: 0.634-0.813), the diagnostic critical value of relative expression was 1.78, the sensitivity was 66.7%, and the specificity was 73.3%. The maximum AUC of combined detection of APE1 and miR183 was 0.829 (95%CI: 0.756-0.903), the sensitivity was 83.3%, and the specificity was 70.0%.Conclusion The two indicators of serum APE1 protein and miR183 have certain value in the diagnosis of hepatocellular carcinoma, and the combined detection of the two indicators can improve the ability to detect the primary hepatocellular carcinoma.

Key words: Primary hepatocellular carcinoma, Apurinic/apyrimidinic endonuclease 1, microRNA183, Combined detection